WEGOVY
McDonald’s downgraded amid Ozempic craze - investors worry fast food losing charm, stock under pressure
McDonald's stock was downgraded by analysts following concerns that weight-loss drugs like Ozempic could curb fast-food demand. Analysts suggested that these drugs, which reduce appetite, might lead to a significant drop in customer visits, potentially costing the company millions in revenue.
Weight-loss drug bulks up sales as patients upgrade dosage
Eli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three months. Young adults in their 30s and 40s are showing significant interest, with many upgrading to higher doses. While experts acknowledge its potential, they caution about long-term efficacy, side effects, and affordability for the Indian population.
This disease might be silently killing millions quietly, says research. Are you at risk?
A new international study has found that over 15 million people across the US, UK, Germany, and France are unknowingly living with metabolic dysfunction-associated steatohepatitis (MASH), the most aggressive form of fatty liver disease. Despite its serious risks—including liver failure, cancer, and other chronic illnesses—more than three-quarters of affected individuals remain undiagnosed. Researchers are urging wider screening, especially among those with obesity and type 2 diabetes, and highlighting the potential role of weight-loss medications in treatment.
Big fat legal war bursts out ahead of Novo Nordisk's Wegovy launch
Novo Nordisk has filed a lawsuit in Delhi High Court. The suit aims to stop Dr Reddy's Laboratories and OneSource from selling semaglutide in India. Semaglutide is the active ingredient in Wegovy. The court has restrained the Indian companies from selling the drug domestically. However, they can still manufacture and export it. The next hearing is scheduled for August 19.
Leena Tiwari: Meet the billionaire owner of India's costliest flats
Leena Tewari, chairperson of USV, made headlines with the purchase of luxury apartments in Mumbai for Rs 639 crore, India's most expensive residential property deal. USV, known for brands like Glycomet and Ecosprin, remains a family-run company with Rs 4,840 crore in FY24 revenues. Despite challenges, USV aims to strengthen its position in the insulin business and develop copies of semaglutide.
Who is Leena Tewari? Owner of India's costliest flats worth over Rs 700 crore, spanning 22,572 sq ft in Worli
Leena Tewari, USV Pharmaceuticals chairperson, purchases luxury Mumbai apartments for Rs 639 crore. This deal sets a new real estate record. Tewari, with a $3.9 billion net worth, maintains a low profile. USV, a family-run company, reports Rs 4,840 crore revenue. It focuses on diabetes drugs like Glycomet.
- Go To Page 1
Zydus working on single pen device for adjustable Semaglutide doses
Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It targets both diabetes and obesity. Clinical trials are underway in India. Zydus plans a day 1 launch in India. They will explore partnerships for emerging markets. The device aims to improve patient convenience. Some companies have shown interest in co-marketing.
Domestic drug companies in a sweet spot as global players look beyond insulin
Indian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin and more type 1 diabetes cases are helping them. Domestic companies accounted for 25% of the market. Multinational companies are shifting focus. This shift creates opportunities for Indian companies. Lupin acquired Huminsulin brand.
Obesity drug maker Novo Nordisk ousts CEO as competition weighs
Novo Nordisk CEO Lars Fruergaard Jorgensen will step down amidst growing concerns about the company's competitive position in the obesity drug market. Increased competition from Eli Lilly, particularly with Zepbound surpassing Wegovy prescriptions in the U.S., and investor disappointment with Novo Nordisk's drug pipeline have contributed to a significant share price decline.
US stock futures edge higher as S&P 500 eyes fifth gain on China tariff truce, cooling inflation, and Fed cut bets
US Stock futures rise as the S&P 500 aims for a fifth straight gain, lifted by easing U.S.-China trade tensions and softer inflation data. Dow and Nasdaq futures also edged up after a 90-day tariff pause and signs that inflation is cooling. A drop in wholesale prices and hopes for Fed rate cuts are giving investors reason to stay optimistic. Meanwhile, Walmart warned of possible price hikes, Novo Nordisk's CEO steps down, and Buffett boosts his stake in Constellation Brands. Read how markets are reacting and what key data could move stocks next.
European shares rise as US, China hail 'constructive' Geneva trade talks
European shares rose on Monday, as investors welcomed signs of progress in U.S.-China trade talks aimed at cooling a trade war between the world's two largest economies and dispelling some of the uncertainty clouding financial markets.
Ozempic injections for weight loss 'could lower cancer risk', researchers say
Recent research suggests that Ozempic and other GLP-1 receptor agonists, commonly used for weight loss, may offer unexpected anti-cancer benefits, particularly for obesity-related cancers. Studies indicate these medications could lower cancer risk independently of weight reduction, potentially by reducing inflammation and enhancing immune function. Further research is needed to fully understand their anti-cancer potential.
Mounjaro is now a heavyweight in weight-loss fight
Mounjaro, a weight-loss drug by Eli Lilly, saw a huge jump in sales after its India launch. Sales of Mounjaro injections increased significantly in April. Doctors are observing its effectiveness and side effects on Indian patients. Obesity is prevalent in India. Affordability and tolerance are key factors. Studies suggest constipation is a common side effect.
US, Chinese stocks up before trade talks, Fed move
US and Chinese stocks experienced gains amid anticipation for US-China trade discussions and the Federal Reserve's interest-rate decision. European markets showed caution, while geopolitical tensions impacted Pakistan's stock market. Disney's shares surged following positive sales figures, while pharmaceutical stocks faced challenges due to regulatory changes and revised forecasts.
European shares edge lower as investors await tariff updates
In a TV interview aired on Sunday, Trump said he would not attempt to remove Fed Chair Jerome Powell but repeated calls for lower interest rates and called the Chair a "stiff".
With weight-loss drugs, going under the knife may lose edge
The introduction of weight-loss medications like Mounjaro and Wegovy in India may lead to a decrease in bariatric surgeries as obese individuals with a BMI of 30-35 may opt for drugs first. While surgeries can result in 70-80% weight loss, drugs offer a less invasive option, though potentially less effective at 15-20%.
Madrid Open: Jack Draper enters semi-finals, overtakes Novak Djokovic in ATP rankings
British No 1 Jack Draper has entered the semifinals of the Mutua Madrid Open after his 6-0, 6-4 victory against Italy's Matteo Arnaldi on Thursday. He is now set to enter the Top 5 of the PIF ATP Rankings, leaving behind 24-time Grand Slam champion Novak Djokovic.
ESA’s new biomass satellite could revolutionize how we study Earth’s forests — Here’s how it works
The ESA launched Biomass aboard a Vega-C rocket earlier this week. The launch vehicle blasted off from Kourou in French Guiana. Biomass is expected to revolutionize humanity's understanding of Earth's forests and the impact that human activities have on them.
Tina Fey’s The Four Seasons just dropped — Here’s what viewers can’t stop talking about
Tina Fey’s latest series, The Four Seasons, released on Netflix on May 1. Adapted from Alan Alda’s 1981 film of the same name, this is an eight-episode show. It follows the journey of three long-time couples as they navigate divorce, love, and life’s ups and downs across four seasonal getaways. Read on to know what the audience thinks about it.
Weight loss drug Wegovy can help fight deadly liver disease MASH, claims new study
A latest study has shown promising results in people suffering from metabolic dysfunction-associated steatohepatitis (MASH), an advanced form of the liver disease, with about two-third of them being effectively treated by weight loss drug Wegovy. Here's all you need to know about the study.
Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity
Novo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the anticipated launch of its weight-loss drug Wegovy. This move has prompted other major insulin manufacturers like Lupin, Eris, and Eli Lilly to increase their production capabilities to address the potential supply gap.
Novo Nordisk to discontinue Human Mixtard, India's largest selling insulin brand
Novo Nordisk will discontinue Human Mixtard, a top-selling insulin in India. This decision aligns with the company's global strategy. They will prioritize newer, patented therapies like Ozempic and Wegovy. The company plans to introduce these therapies in India this year. While vials will still be available, pen devices, preferred by many, may become less accessible.
Shedding weight may no longer be a prickly issue as Eli Lilly’s weight-loss pill moves closer to launch
Eli Lilly's new oral weight-loss pill, orforglipron, shows promise in late-stage trials across countries like India and the US. Participants experienced an average weight loss of 7.2 kg with the 36 mg dose over 40 weeks. While less potent than injectable Wegovy, orforglipron offers a needle-free alternative, potentially easing distribution, especially in emerging markets.
New study on Ozempic reveals shocking effects on eating habits
A new study into GLP-1RA drugs provides previously unknown insights into the impact this class of drugs may have on eating habits. The study was helmed by the US Department of Agricultural Economics & Agribusiness.
Pfizer scraps weight loss pill after liver injury: What it means for the future of obesity drugs?
Pfizer halted development of its weight-loss pill, danuglipron, after liver injury concerns surfaced during trials, impacting its ambition to compete with Novo Nordisk and Eli Lilly. This setback caused Pfizer's stock to dip, while rivals saw shares surge. Despite this, Pfizer is still pursuing other obesity treatments, but faces an uphill battle to catch up in the competitive market.
Pfizer ends development of weight-loss pill danuglipron
Pfizer has halted the development of its experimental weight-loss pill, danuglipron, following a trial participant's liver injury, which resolved after discontinuing the medication. This decision follows earlier setbacks with a twice-daily version due to significant side effects. Despite the setback, Pfizer remains committed to obesity treatment, shifting focus to an oral drug targeting GIPR and other research programs.
Weight is over! Pharma companies race to make weight-loss drug semaglutide
Indian drugmakers, including Dr. Reddy's and Zydus Lifesciences, are investing heavily in manufacturing capabilities to launch generic versions of Novo Nordisk's Wegovy and Ozempic as patents expire. These companies are developing novel technologies and aligning capacities for delivery pens, targeting both the Indian market and exports.
India's anti-obesity drug market has grown more than fourfold in the last five years
India's anti-obesity drug market has surged, growing over fourfold in five years, reaching ₹576 crore by March 2025, driven by lifestyle diseases and increased affordability. Semaglutide, particularly Rybelsus from Novo Nordisk, dominates the market, accounting for 69% of sales. The introduction of Mounjaro by Eli Lilly has further fueled acceptance, with Novo Nordisk planning to launch Wegovy soon.
Novo Nordisk readies to bring weight-loss drug Wegovy to India
Danish pharmaceutical company Novo Nordisk is set to launch its anti-diabetes and weight-loss drug Wegovy in India, aiming to outperform Eli Lilly's Mounjaro. Regulatory approval for Wegovy's cardiovascular benefits has been granted, pending final approval, allowing cardiologists to prescribe it.
Load More
